Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy for Inoperable Malignant Bowel Obstruction
NCT04027348Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of Octreotide long-acting injection, dexamethasone, metoclopramide in malignant bowel obstruction (MBO), sponsored by Roswell Park Comprehensive Cancer Center. Started Jun 2019; status: terminated.
02
Drugs
Octreotide long-acting injectiondexamethasonemetoclopramide
03
Conditions
malignant bowel obstruction (MBO)
Beyond the preview
Go deeper on NCT04027348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027348.